APC Stock Overview
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.
+ 2 more risks
Advanced Proteome Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.14|
|52 Week High||CA$0.34|
|52 Week Low||CA$0.085|
|1 Month Change||16.67%|
|3 Month Change||27.27%|
|1 Year Change||-53.33%|
|3 Year Change||21.74%|
|5 Year Change||-74.54%|
|Change since IPO||-96.32%|
Recent News & Updates
|APC||CA Biotechs||CA Market|
Return vs Industry: APC underperformed the Canadian Biotechs industry which returned 11.1% over the past year.
Return vs Market: APC underperformed the Canadian Market which returned 0.7% over the past year.
|APC Average Weekly Movement||42.7%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: APC is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 43% a week.
Volatility Over Time: APC's weekly volatility has increased from 28% to 43% over the past year.
About the Company
|n/a||n/a||Paul John Woodward||https://www.advancedproteome.com|
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation.
Advanced Proteome Therapeutics Fundamentals Summary
|APC fundamental statistics|
Is APC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.025|
|Net Profit Margin||0.00%|
How did APC perform over the long term?See historical performance and comparison
Is APC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for APC?
Other financial metrics that can be useful for relative valuation.
|What is APC's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does APC's PE Ratio compare to its peers?
|APC PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
IBT IBEX Technologies
WLLW Willow Biosciences
MBX Microbix Biosystems
APC Advanced Proteome Therapeutics
Price-To-Earnings vs Peers: APC is good value based on its Price-To-Earnings Ratio (4.4x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does APC's PE Ratio compare vs other companies in the North American Biotechs Industry?
Price-To-Earnings vs Industry: APC is good value based on its Price-To-Earnings Ratio (4.4x) compared to the North American Biotechs industry average (15.8x)
Price to Earnings Ratio vs Fair Ratio
What is APC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||4.4x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate APC's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of APC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate APC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate APC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Advanced Proteome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of APC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Advanced Proteome Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Advanced Proteome Therapeutics performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APC has high quality earnings.
Growing Profit Margin: APC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: APC has become profitable over the past 5 years, growing earnings by 4.2% per year.
Accelerating Growth: APC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: APC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: APC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Advanced Proteome Therapeutics's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: APC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: APC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: APC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if APC's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as APC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul John Woodward (60 yo)
Mr. Paul John Courtney Woodward has been Chief Financial Officer and Director at Railtown AI Technologies Inc. since August 18, 2016 and served as its President and Chief Executive Officer from August 18,...
CEO Compensation Analysis
Compensation vs Market: Paul John's total compensation ($USD70.00K) is below average for companies of similar size in the Canadian market ($USD186.79K).
Compensation vs Earnings: Paul John's compensation has been consistent with company performance over the past year.
Experienced Management: APC's management team is considered experienced (3.7 years average tenure).
Experienced Board: APC's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.
Advanced Proteome Therapeutics Corporation's employee growth, exchange listings and data sources
- Name: Advanced Proteome Therapeutics Corporation
- Ticker: APC
- Exchange: TSXV
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$5.555m
- Shares outstanding: 39.68m
- Website: https://www.advancedproteome.com
- Advanced Proteome Therapeutics Corporation
- 8337 Eastlake Drive
- Suite 104
- British Columbia
- V5A 4W2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.